Invivyd Reports Q1 2026 Results, Secures $20M via ATM, Advances VYD2311 Program

summarizeSummary

Invivyd reported increased Q1 2026 net loss and operating expenses, but secured $20 million via an ATM offering to extend its cash runway while advancing its VYD2311 clinical program with positive regulatory and safety updates.

check_boxKey Events · Earnings and Guidance · IVVD

• Q1 2026 Financial Results

  Reported a net loss of $41.4 million for Q1 2026, significantly higher than $16.3 million in Q1 2025, primarily due to increased R&D and SG&A expenses. PEMGARDA net product revenue grew 22% year-over-year to $13.7 million.

• Capital Raise via ATM Offering

  Raised approximately $20 million in gross proceeds through an at-the-market (ATM) offering facility in April 2026, bolstering cash and cash equivalents to support operations through the VYD2311 pivotal data readout.

• VYD2311 Clinical Program Progress

  The DECLARATION pivotal trial for VYD2311 saw rapid enrollment and positive Independent Data Monitoring Committee (IDMC) recommendations, including reduced post-dose monitoring time and expanded patient eligibility. FDA alignment was also achieved for pediatric and comparative safety trials.

• DECLARATION Data Anticipated Q3 2026

  Top-line data for the DECLARATION pivotal clinical trial for VYD2311 is now anticipated in Q3 2026, a modest shift of approximately two months from original 'mid-year' guidance, due to trial upsizing.

auto_awesomeAnalysis · IVVD · Life Sciences

Invivyd, Inc. reported a significant increase in net loss for Q1 2026, more than doubling year-over-year, driven by higher R&D and SG&A expenses as the company advances its lead VYD2311 program. Despite this increased cash burn, the company successfully raised approximately $20 million through an at-the-market (ATM) offering in April 2026, which is crucial for extending its cash runway, especially given the 'going concern' warning in its last 10-K. Positive clinical updates for VYD2311, including favorable IDMC recommendations and FDA alignment for pediatric and comparative safety trials, provide a clearer path forward, though top-line data for the DECLARATION trial is now anticipated in Q3 2026, a slight delay.